

# Index

- A**  
Abrikossoff tumors, *see* Granular cell tumors (GCTs)  
Acinar cell carcinoma (ACC), 11, 163, 164  
Activated B-cell (ABC), 125, 254, 276  
Acute inflammatory effusion, 241  
Acute lymphoblastic leukemia/lymphoma (ALL), 283, 284  
Adenocarcinoma (ADC), 13, 117–119, 242  
    *ALK* rearrangement, 119  
    esophageal carcinoma, 140  
    lepidic growth pattern, 118  
    not otherwise specified, 118  
    pleomorphic features, 119  
    prostate, 192  
    signet ring cell feature, 119  
    solid growth pattern, 118  
    of stomach, 140  
Adenocarcinoma with lepidic growth pattern, 118  
Adenoid cystic carcinoma (ACC), 10, 11, 74, 90  
Adipose tissue, 14, 55, 56, 96, 105  
Adrenal cortical adenoma, 199, 202, 205, 206, 212, 213  
Adrenal cortical carcinoma, 195, 211, 212  
Adrenal gland cytology, 214–219  
    adrenal cortical adenoma, 205, 206  
    adrenal cortical carcinoma, 211, 212  
    benign adrenal cortical cells, 202, 203  
    cortex, 199  
    FNA, 199, 200  
    FNA biopsy, 199  
    IHC markers, 206, 214  
    medulla, 199  
    metastasis  
        breast carcinoma, 215  
        carcinoma of the prostate, 216  
        endometrioid adenocarcinoma, 218, 219  
        HCC, 216, 217  
        lung adenocarcinoma, 214–215  
        melanoma, 218  
        mucinous adenocarcinoma of small bowel, 214  
        small-cell carcinoma, 217  
        squamous cell carcinoma of esophagus, 215  
        urothelial cell carcinoma, 217–218  
    in pediatric patients, 199  
    pheochromocytomas, 212, 213  
    steroid hormone-producing cortex, 206  
Alcohol-fixed smear, pleomorphic ILC, 69  
 $\alpha$ -fetoprotein (AFP), 181  
Alveolar macrophages, 104, 105, 112, 114, 118, 119, 128  
Amphophilic granular cytoplasm, 60  
Amyloid nodule, 26  
Anal cytology  
    adequacy, 147  
    biomarkers, 153  
    glandular cell abnormalities, 152  
    infections, 147  
    NILM, 147  
    reporting, 147  
    sampling, 146  
    squamous cell abnormalities, 150  
Anal glands, ductal carcinoma, 153  
Anal intraepithelial neoplasia III (AIN III), 152  
Anal Pap test, 148, 149, 151  
Anal squamous cell carcinoma, *see* Squamous cell carcinoma (SqCC)  
Anaplastic large-cell lymphoma (ALCL), 282, 283  
Anaplastic thyroid carcinoma (ATC), 27, 36  
Anaplastic, malignant nuclei, 65  
Ancillary test, 2, 20, 32, 44, 226, 235, 259, 273  
Androgen receptor (AR), 76, 81  
Angioimmunoblastic T-cell lymphoma (AITL), 282  
Angiomyolipoma (AML), 205, 285  
Angular cellular clusters, 70–72  
Antler-like clusters, 48, 49  
Anucleated orthokeratinized squamous cells, 135  
Apocrine breast carcinoma (ABC)  
    differential diagnosis, 81  
    imaging technique, 79  
    molecular profile, 81  
Apocrine metaplasia, 46, 50  
Ascites, 235, 241, 282  
Aspergillosis, 107, 114  
*Aspergillus*, 114  
Atypia of undetermined significance (AUS), 37–39  
Atypical carcinoids, 121, 122  
Atypical ductal hyperplasia (ADH), 87  
Atypical squamous cells, 5, 150  
Atypical squamous cells of unknown significance (ASC-US), 150  
Atypical urothelial cells, 227, 228  
Autosomal dominant polycystic kidney disease, 176
- B**  
Baby boomer population, 180  
Bacillus Calmette-Guérin (BCG), 224, 226  
BAL procedure, 111  
Balloon abrasive cytology, 133  
Barrett's esophagus (BE), 138, 139  
Basal cell adenoma, 7  
Basal cells, 222, 223  
Basaloid neoplasm, 7  
Basaloid squamous cell carcinoma, 120  
Bcl2-negative, 81, 273  
*BCL6* gene, 125, 254  
Beckwith-Wiedemann syndrome, 183  
Benign adrenal cortical cells, 202, 203  
Benign adult female breast lobe, 45

- Benign bile duct epithelium, 174, 175  
 Benign bronchial epithelium, 106  
 Benign effusions, 235  
 Benign entities, 66  
 Benign epithelial neoplasms  
   basal cell adenoma, 7  
   basaloid neoplasm, 7  
   cellular pleomorphic adenoma, 6  
   oncocytoma, 8  
   pleomorphic adenoma, 5, 6  
   Warthin tumor, 6, 7  
 Benign histiocytes, 239  
 Benign kidney tubular cells, 202  
 Benign liver cells, 174, 175, 178, 179, 181  
 Benign mesothelial cells, 111, 236  
   in clusters, 237  
   with window between cells, 237  
 Benign pheochromocytoma, 212  
 Benign reactive lymph nodes, 260  
 Benign renal cysts, 203  
 Benign renal tubular cells, 202  
 Bethesda classification system, 221  
 Bile duct brushings, 169, 170  
 Bile duct epithelial cells, 174, 175, 178  
 Bile duct hamartoma, 176  
 Biliary hamartoma, 176  
 Birefringent calcium oxalate crystals, 107, 114  
 Black adenoma, 205  
 Black thyroid, 26  
 Bladder urothelial cell carcinoma, 252, 253  
 Blastomycosis, 106, 115  
 Blind technique, 104  
 Blister cells, 187  
 B-mode sonography, 82  
 Bosniak classification, 203  
 Breast adenoid cystic carcinoma (BACC), 90–92  
 Breast carcinoma, 86–90, 189, 215  
   invasive ductal carcinoma NOS, 62  
   MBC, 77–79  
   nuclear membrane irregularity, 62  
   osteoclast-like giant cells, 65  
   papillary breast carcinomas  
   cytology, 87–89  
   differential diagnosis, 90  
   imaging technique, 86–87  
   pleomorphic lobular carcinoma, 69  
   primary neuroendocrine tumor, 95–96  
   tubular breast carcinoma, 70–74  
 Breast cytology  
   benign breast lesions  
   FA, 48–51  
   fat necrosis, 53–57  
   FCC, 46  
   GCTs, 59–60  
   granulomatous mastitis, 60–61  
   lactating adenoma, 53  
   lipoma, 57–58  
   PBD, 46  
   subareolar breast abscess, 58–59  
   breast carcinoma  
   ILC, 66–68  
   invasive ductal carcinoma NOS, 62–63  
   invasive ductal carcinoma, osteoclast-like giant cells, 63–66  
   pleomorphic lobular carcinoma, 68–69  
   cytoarchitecture, 44  
   FNA, 43  
   adequacy evaluation, FNA, 44  
   indicators, 44  
   specimen, 45  
   gynecomastia, causes, 96  
   high-magnification evaluation, 44  
   low-magnification evaluation, 44  
   Papanicolaou-stained smears, 64  
   PBD, 43  
   WHO classification  
   invasive breast carcinomas, 64  
   papillary breast lesions, 86  
 Bronchial basal cells, 106, 109  
 Bronchial epithelium hyperplasia, 108  
 Bronchial reserve cells, 109  
 Bronchoalveolar carcinoma, 117  
 Bronchoalveolar lavage (BAL), 105, 111  
 Bronchoalveolar macrophages, 106, 110  
 Brush cytology, 133, 134, 137, 139, 140, 145
- C**  
 Calcium oxalate crystals, 114  
 California fever, 113  
 Calretinin, 206, 212, 238, 239, 243, 245, 246, 250  
*Candida* esophagitis, 137  
*Candida* infections, 115  
 Candidiasis, 107, 115  
 Carcinoid tumor, 68, 95, 121–123, 190  
 Carcinoma  
   ex pleomorphic adenoma, 9  
   GI cytology  
   clinical presentation, 135  
   definition, 135  
   differential diagnosis, 136  
   features of, 136  
   molecular changes, 136  
   prostate, 216  
 Carney-Stratakis syndrome, 144, 145  
 Caroli's disease, 176  
 Cartilage, 84, 110  
 ccRCC, *see* Clear cell renal cell carcinoma (ccRCC)  
 Cell-cell adhesion molecules, 84  
 Cellular pleomorphic adenoma, 6  
 Cellular smears, 6, 12, 15, 16, 48, 53, 57, 60, 62, 66, 68, 76, 79, 88, 195  
 Cellular stroma, 48, 50–53  
 Cercariform cells, 192, 211, 217  
 Charcot-Leyden crystals, 107, 237, 240  
 Cholangiocarcinoma, 176, 179, 181, 184, 188, 190  
 Chromophobe renal cell carcinoma, 204, 206, 210  
 Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 268–270  
 Ciliated bronchial epithelium, clusters, 108  
 Cirrhosis, 96, 176  
 Classical Hodgkin lymphoma (cHL), 186, 281  
 Clear cell renal cell carcinoma (ccRCC), 199, 201–203, 208, 212  
*Coccidioides immitis*, 113  
 Coccidioidomycosis, 113  
 Colloid breast cancer, *see* Mucinous breast cancer  
 Colloid nodules, 21  
 Colon cytology, 146  
 Colonic adenocarcinoma, 187, 188, 214  
 Colorectal adenocarcinomas, 247  
 Conventional transbronchial needle aspiration (TBNA), 104, 105  
*Corynebacterium accolens*, 60  
 Cryptococcal thyroiditis, 25  
 Cryptococcosis, 106, 115  
*Cryptococcus neoformans*, 115

Curschmann spiral, 104, 107  
 Cystic renal cell carcinoma, 208, 209  
 Cytoentrifuge, 236  
 Cytokeratins, 79, 125, 128, 130, 142, 183, 185–187, 191, 192, 195, 196, 206, 209, 211–213, 218, 243, 250, 253–255  
 Cytological atypia, 117, 195, 201  
 Cytological features of benign conditions, 174, 201  
 Cytological features of malignant tumors, 206–207  
 Cytomegalovirus (CMV) esophagitis, 137  
 Cytomorphology, 122, 144, 159, 162, 163, 180, 187, 206, 214, 222, 229, 236, 251, 259, 287  
 Cytoplasmic polychromasia, 226  
 Cytoskeleton, 79, 84

## D

De Quervain's thyroiditis, 24  
 Dermatofibrosarcoma protuberans, 84  
 Dermatopathic lymphadenitis, 261, 263  
 Desert rheumatism, 113  
 Diff-Quik methods, 175, 236  
 Diff-Quik stain, 43, 177, 189, 202  
 Diffuse hyperplastic oncocytosis, 3  
 Diffuse large B-cell lymphoma (DLBCL), 15, 125, 143, 185, 213, 254, 276  
 Diffuse malignant mesothelioma (DMM), 243  
 Dirty necrosis, 218  
 Disheveled-associated activator of morphogenesis 1 (*DAAMI*), 79  
 Ductal adenoma, 74  
 Ductal epithelium proliferation, 47  
 Duodenal cytology, 145  
 Duodenal epithelium, 158  
 Dyskeratosis congenita, 136  
 Dysplasia, 135, 136, 139  
   clinical presentation, 135–136  
   definition, 135  
   differential diagnosis, 136  
   features of, 136  
   molecular changes, 136

## E

Echinococcal cysts, *see* Hydatid cysts  
 Echoendoscopy, 133, 134  
 Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), 105–108  
 Endometrioid adenocarcinoma, 197, 218, 219  
 Endometrioid carcinoma, 127, 197  
 Endometriosis, 252, 264  
 Endosalpingiosis, 241, 252, 264  
 Endoscopic retrograde cholangiopancreatography (ERCP), 157  
 Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), 105, 106, 157, 173  
 Endosporulating fungus, 57  
*Entamoeba histolytica*, 149  
 Eosinophilic cytoplasm, 77, 79, 80, 124, 190, 192, 194, 195, 202, 205, 208, 217, 255  
 Eosinophilic effusion  
   with Charcot-Leyden crystals, 240  
   with numerous eosinophils, 240  
 Eosinophilic granular cytoplasm, 60, 79, 80, 202  
 Eosinophilic pleural effusion (EPE), 240  
 Eosinophils, 114, 204, 237, 240, 282  
 Epithelial-mesenchymal transition (EMT), 84  
 Epithelioid hemangioendothelioma (EHE), 124, 187  
 Epithelioid histiocytes, 4, 60, 112  
 Epithelioid synovial sarcoma, 130

Epstein-Barr virus (EBV), 185, 186, 244  
 ER- $\alpha$ -negative, 81  
 Esophageal adenocarcinoma, 138, 140  
 Esophageal carcinoma  
   adenocarcinoma, 140  
   squamous cell carcinoma of esophagus, 139, 140  
 Esophageal cytology  
   BE, 138, 139  
   esophageal carcinoma  
     adenocarcinoma, 140  
     squamous cell carcinoma of esophagus, 139, 140  
   esophageal infections, 136, 137  
   reactive and reparative changes, 138  
 Esophageal infections, 136, 137  
 Ewing's sarcoma, 194, 196  
 Excision repair cross-complementation group 1 protein (ERCC1), 81  
 Exfoliative cytology, 133, 136  
 Extracellular matrix (ECM), 74, 84, 85, 260  
 Extracellular mucin, 75, 76, 166, 167, 212  
 Extramedullary hematopoiesis (EMH), 174, 177

## F

False-positive diagnosis, of malignancy, 59  
 Fat necrosis  
   clinical condition, 54  
   cytology, 55  
   differential diagnosis, 57  
   imaging technique, 54  
   reconstructive surgery/radiation therapy, 54  
 Fatty liver changes, 177  
 Ferruginous bodies, 107  
 Fibroadenoma (FA), 53, 74  
   clinical, 48  
   cytology, 48  
   differential diagnosis, 51  
   imaging technique, 48  
   molecular profile, 51  
   specimen, 48  
   stromal benign tumor, 48  
 Fibroblast proliferation, 62  
 Fibrocystic change (FCC), 46  
 Fibroepithelial breast lesions, 53  
 Fibroepithelial tumor, 51  
 Fibrous/desmoplastic stroma, 62  
 Fibrovascular stroma, 76  
 Fine needle aspiration (FNA), 19, 43, 45, 46, 104, 199, 200  
   advantages, 19  
   biopsy, 199  
   follicular hyperplasia, 260  
   GI cytology, 134  
   thyroid cytology (*see* Thyroid nodules)  
 Fluorescence in situ hybridization (FISH), 104, 169, 170, 243, 259, 270, 272, 274, 276  
 Focal nodular hyperplasia (FNH), 178  
 Follicular hyperplasia  
   differential diagnosis, 260  
   flow cytometry, 260–262  
   FNA, 260  
   molecular study, 261, 262  
 Follicular lesion of undetermined significance (FLUS), 19, 37  
 Follicular lymphoma (FL), 15, 272–275  
 Follicular neoplasm (FN), 20, 39  
 Formalin-fixed, paraffin-embedded (FFPE) tissue, 43  
 Fragments of cartilage, 110  
 Functioning testicular tumors, 96

- G**
- Galactography, 86
  - Gastric cytology
    - gastric infections, 140
    - gastric malignant disease
      - adenocarcinoma of stomach, 140, 141
      - gastric lymphomas, 142, 143
      - GIST, 143–145
      - neuroendocrine tumors, 142
    - granular cell tumor, 140
  - Gastric gastrointestinal stromal tumor, 144, 145
  - Gastric granular cell tumor, 141
  - Gastric infections, 140
  - Gastric lymphoma, 142
    - clinical aspects, 142
    - DLBCL of stomach, 143
    - MALT lymphomas, 142, 143
    - primary gastric lymphoma, 142
    - primary Hodgkin lymphoma of stomach, 143
  - Gastric neuroendocrine tumors
    - grading of, 143
    - WHO classification, 142
  - Gastric signet ring carcinoma, 141
  - Gastrointestinal (GI) cytology
    - anal cytology, 146
    - adequacy, 147
    - biomarkers, 153
    - glandular cell abnormalities, 152
    - infections, 147
    - NILM, 147
    - reporting, 147
    - sampling, 146
    - squamous cell abnormalities, 150
  - benign and malignant processes, characteristics of, 138
  - benign cellular changes, 135
  - colon cytology, 146
  - cytologic findings, 134
  - duodenal cytology, 145
  - dysplasia and carcinoma
    - clinical presentation, 135
    - definition, 135
    - differential diagnosis, 136
    - features of, 136
    - molecular changes, 136
  - esophageal cytology, 136
    - adenocarcinoma, 140
    - BE, 138, 139
    - esophageal infections, 136, 137
    - reactive and reparative changes, 138
    - squamous cell carcinoma of esophagus, 139, 140
  - gastric adenocarcinoma, molecular changes, 141
  - gastric cytology
    - adenocarcinoma of stomach, 140, 141
    - gastric infections, 140
    - gastric lymphomas, 142, 143
    - GIST, 143–145
    - granular cell tumor, 140
    - neuroendocrine tumors, 142
  - gastric neuroendocrine tumors
    - grading of, 143
    - WHO classification, 142
  - oral cancer, 135
  - papanicolaou, 135
  - sample types and preparation
    - balloon abrasive cytology, 133
    - brush cytology, 133
    - exfoliative cytology, 133
  - FNA, 134
    - salvage cytology, 134
  - Gastrointestinal stromal tumor (GIST), 143–145, 193
  - GATA-3, 126, 128, 253
  - Germinal center B-cell (GCB) DLBCL, 125, 143, 254
  - Giant multinucleated histiocytes, 239
  - Glandular cell abnormalities, 152
  - Gleason grade V, 192, 216
  - Glomeruli, 201, 202
  - Glucose transporter-1 (GLUT-1), 179, 243
  - Goblet cell hyperplasia, 108, 119, 129
  - Goblet cells, 105, 106, 138, 145, 146
  - Granular cell tumors (GCTs), 14, 140
    - caveat, 60
    - clinical condition, 59
    - cytology, 59–60
    - malignant, 60
  - Granular cytoplasm, 60, 81
  - Granulomas, 24, 43, 61, 106, 112, 134, 226, 263
  - Granulomatous aspergillosis, 25
  - Granulomatous inflammation, 57, 59, 60, 112
  - Granulomatous lymphadenitis, 263
  - Granulomatous mastitis
    - caveat, 61
    - clinical condition, 60
    - cytology, 60
    - differential diagnosis, 60
    - imaging technique, 60
  - Granulomatous sialadenitis, 4
  - Gray zone nodules, 20
- H**
- Head and neck squamous cell carcinomas (HNSCC), 135, 136
  - Helicobacter pylori*, 140
  - Hemangioma, 14, 104, 173, 174, 178, 179, 187, 286
  - Hematolymphoid tumors, 1, 15
  - Hematoxylin and eosin (H&E), 43, 204
  - Hematoxylin body, 237
  - Hep Par 1 antibody, 181
  - Hepatic adenoma, 174, 176, 178
  - Hepatic hemangiomas, 179
  - Hepatic steatosis, 177
  - Hepatoblastoma, 180, 183
  - Hepatocellular carcinoma (HCC), 176–178, 184, 185, 188, 191, 195, 213, 218
    - adrenal gland cytology, 216, 217
    - cytological diagnosis, 180
    - endothelial wrapping, 181
    - feature of, 181
    - fibrolamellar variant of, 183
    - Hep Par 1, 181
    - IHC markers, 181
    - incidence of, 180
    - melanoma, 193
    - moderately differentiated, 216
    - poorly differentiated tumor, 182, 216
    - well-differentiated, 181, 182
    - $\alpha$ -fetoprotein (AFP), 181
  - Herpes simplex virus (HSV), 226
  - Herpesvirus, 137, 147, 149
  - High-grade atypical squamous cells (ASC-H), 150
  - High-grade B-cell lymphoma, 36
  - High-grade carcinoma ex pleomorphic adenoma, 10
  - High-grade squamous intraepithelial lesion (HSIL) cells, 150, 151
  - High-grade urothelial carcinoma, 221, 222, 226–231
  - High-grade urothelial neoplasms, 229, 230

- Histiocytes, 237, 239  
 Histiocytic infiltration, 55  
 Histoplasmosis, 106, 115  
 Hodgkin and Reed-Sternberg (HRS) tumor, 186  
 Hodgkin lymphoma (HL), 93, 177, 186  
 Hormone-expressing tumors, 66  
 Hürthle cell type, 39–42  
 Hydatid cysts, 179  
 Hyperchromasia, 9, 62, 63, 69, 70, 136, 192, 201, 223, 226–228  
 Hyperestrinism, 96  
 Hypoechoogenicity, 53  
 Hypoxia-related gene clusters, 51
- I**  
 Immunohistochemistry (IHC), 92, 187, 191, 193, 196, 197, 206  
 Immunopattern, 119, 246, 254  
 Incidentalomas, 199  
 Infections, anal cytology, 147  
 Infectious thyroiditis, 25  
 Inflammatory myofibroblastic tumor (IMT), 124  
 Inflammatory/infectious lymphadenitis, 263–264  
 Intermediate cells, 8, 222, 223  
 Intracytoplasmic lumina, 62, 66  
 Intracytoplasmic mucin secretion, 66  
 Intracytoplasmic vacuoles, 96, 124  
 Intraductal papillary mucinous neoplasm (IPMN), 166, 167  
 Intraductal papilloma (IDP), 51, 86  
 Intramucosal cancer, 139  
 Invasive ductal carcinoma (IDC), 65–66, 89  
   cytology smear, 62  
   not otherwise specified (NOS), 62  
   osteoclast-like giant cells, 63  
     caveat, 66  
     clinical condition, 65  
     cytology, 65  
     differential diagnosis, 66  
     molecular profile, 65–66  
 Invasive lobular carcinoma (ILC)  
   clinical condition, 66  
   cytology, 66, 67  
   differential diagnosis, 68  
   imaging technique, 66  
   molecular profile, 68
- K**  
 Keratinaceous debris, 58  
 Keratinizing squamous cell carcinoma, 15, 120, 136, 139, 150, 152, 189  
 Kidney cytology  
   AML, 205  
   benign renal cysts, 203  
   benign renal tubular cells, 202  
   FNA, 199, 200  
   glomeruli, 201, 202  
   primary tumors  
     ccRCC, 208  
     chromophobe RCC, 206, 210  
     cystic RCC, 208  
     IHC markers, 206  
     papillary RCC, 206, 209, 210  
     RCC, 208  
     sarcomatoid RCC, 209  
     urothelial cell carcinoma, 211  
     Xp11 TRCC, 210  
   RCC, 199  
     renal oncocytoma, 204, 205  
     Ki67 proliferation index, 121, 163, 191, 206  
     Klinefelter's syndrome, 96
- L**  
 Lactating adenoma, 54  
   caveat, 53  
   clinical condition, 53  
   cytology, 53  
   differential diagnosis, 53  
   imaging technique, 53  
 Large-cell carcinoma, 116  
 Large-cell neuroendocrine carcinoma (LCNEC), 121–123  
 Leiomyoma, 14, 144  
 Leiomyosarcoma, 84, 123, 195  
 LEOPARD syndrome, 59  
 Leukoplakia, 135, 136  
 Liesegang ring, 203, 204  
 Lipid-rich carcinoma, 81  
 Lipofuscin stains, 175  
 Lipogranulomatous reaction, 55  
 Lipoma, 14  
   caveat, 58  
   clinical condition, 57  
   cytology, 57  
   differential diagnosis, 58  
   imaging technique, 57  
   molecular profile, 58  
 Lithiasis, 226  
 Liver cell adenoma, *see* Hepatic adenoma  
 Liver cyst  
   needle core biopsy, 173  
   percutaneous fine needle aspiration, 173  
   size, 173  
 Liver cytology  
   benign bile duct epithelium, 175  
   benign liver cells, 175  
   bile duct hamartoma, 176  
   cirrhosis, 176  
   cytological features of benign conditions, 174  
   EMH, 177  
   fatty liver change, 177  
   FNH, 178  
   hepatic adenoma, 178  
   hepatic hemangiomas, 179  
   hydatid cysts, 179  
   metastasis to liver  
   adenocarcinoma of the prostate, 192  
   adrenal cortical carcinoma, 195  
   breast carcinoma, 189  
   colonic adenocarcinoma, 187  
   endometrioid adenocarcinoma, 197  
   GIST, 193  
   leiomyosarcoma, 195  
   lung adenocarcinoma, 188  
   melanoma, 193  
   metastatic carcinoid, 190  
   PEN, 191  
   PNET/Ewing's sarcoma, 196  
   PTC, 196  
   RCC, 190  
   small-cell carcinomas, 191  
   squamous cell carcinomas, 189  
   urothelial cell carcinoma, 192  
   Wilms' tumor, 194  
   primary malignant tumors (*see* Primary malignant tumors)

- Lobular carcinoma in situ (LCIS), 66
- Lobular carcinomas, 68
- Localized malignant mesothelioma (LMM), 243
- Loss of heterozygosity (LOH), 81, 95, 136
- Low-grade myoepithelial carcinoma, 11
- Low-grade squamous intraepithelial lesion (LSIL), 150, 151
- Low-grade urothelial neoplasms, 228–230
- Lung adenocarcinoma, 187, 188, 197, 214, 215
- Lung cancer, 103–106, 112, 119, 245
- Lung parenchyma, 105
- Lung transplantation, 111
- Lymph node cytology
- ancillary test, 259
  - benign reactive lymph nodes, 259, 260
  - cell block, 259
  - cytomorphology, 259
  - diagnosis, 259
  - inflammatory/infectious lymphadenitis, 263–264
  - initial evaluation, 259
  - lymph node inclusions, 264–265
  - lymphomas
    - AITL, 282
    - ALCL, 282, 283
    - ALL, 283, 284
    - cHL, 281
    - CLL/SLL, 268, 269
    - diffuse large B-cell lymphoma, 276
    - follicular lymphoma, 272–274
    - LPL, 277, 278
    - mantle cell lymphoma, 270–272
    - marginal zone lymphoma, 275
    - myeloid sarcoma, 284, 285
    - NLPHL, 279, 280
    - plasma cell neoplasm, 277
    - PMBCL, 279
    - vascular tumors, 286
  - metastatic tumors
    - colorectal adenocarcinoma, 266
    - mammary ductal carcinoma, 265
    - melanoma, 267
    - ovarian papillary serous carcinoma, 267
    - prostate adenocarcinoma, 266
    - renal cell carcinoma, 267
    - small cell carcinoma, 266
    - squamous cell carcinoma, 266
    - thyroid carcinoma, 267
  - reactive lymphoid hyperplasia, 260
    - dermatopathic lymphadenitis, 261, 263
    - follicular hyperplasia (*see* Follicular hyperplasia)
    - follicular hyperplasia histology, 260, 261
    - lymphoma molecular study, 261, 262
  - specimens, 260
- Lymph node inclusions, 264–265
- Lymphocytes, 7, 23, 36, 125, 226, 237, 240, 251, 254, 260, 268, 270, 277–279
- Lymphocytic effusion, 239, 240
- Lymphocytic (Hashimoto's) thyroiditis, 23
- Lymphoepithelial carcinoma, 13
- Lymphoepithelial cyst, 4
- Lymphoglandular body, 237
- Lymphomas, 68
- AITL, 282
  - ALCL, 282, 283
  - ALL, 283, 284
  - cHL, 281
  - CLL/SLL, 268, 269
  - diffuse large B-cell lymphoma, 276–277
  - DLBCL, 185, 213
  - FNAs of, 185
  - follicular lymphoma, 272–274
  - HL, 186
  - LPL, 277, 278
  - malignant nodules, 36
  - mantle cell lymphoma, 270–272
  - marginal zone lymphoma, 275
  - molecular study, 261, 262
  - myeloid sarcoma, 284, 285
  - NLPHL, 279, 280
  - non-Hodgkin lymphoma, 117
  - plasma cell neoplasm, 277
  - PMBCL, 279
  - subtypes, 185
  - vascular tumors, 286
- Lymphoplasmacytic lymphoma (LPL), 277, 278
- Lymphoproliferative disorder, 251, 260
- M**
- Magenta bodies, 189, 237, 248
- Magnetic resonance imaging (MRI), hemangiomas, 179
- Male breast, gynecomastia, 96–97
- Malignant cortical carcinomas, 195
- Malignant fibrous histiocytoma, 84
- Malignant mesothelioma, 239
- with hyperchromatic nuclei, 243
  - with immunohistochemical stains of calretinin, 244
  - with three-dimensional clusters, 243
- Malignant nonpapillary tumors, 87
- Malignant peripheral nerve sheath tumors, 84
- Malignant pheochromocytoma, 212
- Malignant pleural effusion, 235, 241, 242
- bladder urothelial cell carcinoma, 252, 253
  - colorectal adenocarcinomas, 247
  - malignant mesothelioma, 243
  - metastatic adenocarcinomas, 245
  - metastatic breast carcinoma, 247, 248
  - metastatic diffuse large B-cell lymphoma, 254
  - metastatic epithelioid angiosarcoma, 255
  - metastatic leiomyosarcoma, 255
  - metastatic lung adenocarcinoma, 245, 246
  - metastatic melanoma, 253
  - metastatic prostatic adenocarcinoma, 249
  - metastatic sarcomas, 254
  - metastatic signet-ring cell carcinoma, 249
  - metastatic small cell carcinoma, 251
  - metastatic squamous cell carcinoma, 249, 250
  - ovary, metastatic papillary serous carcinoma of, 252
  - PEL, 244
- Malignant primary lung tumors, 116
- ADC, 117–119
  - NETs, 121
    - atypical carcinoid, 122
    - LCNEC, 123
    - SCLC, 122
    - typical carcinoid, 121
  - SqCC, 119, 120
  - uncommon pulmonary tumors
    - DLBCL, 125
    - EHE, 124
    - IMT, 124
    - leiomyosarcoma, 123
    - MALT lymphoma, 125

- Mammography, 48, 54  
Mantle cell lymphoma (MCL), 270–272  
Marginal zone lymphoma (MZL), 185, 275  
Mature fibroadipose tissue, 57, 58  
Medullary breast carcinoma  
  clinical condition, 77  
  cytology, 77  
  differential diagnosis, 79  
  imaging, 77  
Medullary thyroid carcinoma (MTC), 32–34  
Melamed-Wolinska bodies, 192, 217  
Melan-A stains, 193, 218  
Melanin pigment, 128, 193, 211, 218  
Melanoma, 68, 117, 193, 213, 218, 242  
Mesenchymal tumors  
  granular cell tumor, 14  
  leiomyoma, 14  
  lipoma, 14  
  rhabdomyosarcoma, 14  
Mesothelial cell markers, 111, 193  
Mesothelioma, 111, 130, 187, 235, 239, 242, 252  
Metaplastic breast carcinoma (MCB), 63, 66, 81–82, 84  
  chondroid differentiation, 84–86  
  spindle-cell type  
    clinical condition, 81  
    cytology, 82  
    differential diagnosis, 84  
    heterogeneous group, of tumors, 81  
    imaging technique, 81–82  
    molecular characteristics, 84  
Metastatic adenocarcinoma, 245  
  of colon, with necrotic debris, 247  
  of lung  
    focal scalloping borders, 246  
    focal signet-ring cell morphology, 246  
    immunohistochemical stains of BerEP4, 246  
Metastatic bladder urothelial cell carcinoma  
  hyperchromatic nuclei and dense cytoplasm, 253  
  papillary structure, 253  
Metastatic breast carcinoma, 126, 247  
Metastatic carcinoid, 190  
Metastatic colonic adenocarcinoma, 127  
Metastatic colorectal adenocarcinoma, 247, 266  
Metastatic diffuse large B-cell lymphoma, 254  
Metastatic disease, Hodgkin lymphoma, 93  
Metastatic ductal carcinoma of breast, 247  
Metastatic endometrioid adenocarcinoma, 127  
Metastatic epithelioid angiosarcoma, 255  
Metastatic hepatocellular carcinoma, 16, 213, 216  
Metastatic leiomyosarcoma, 255  
  cigar-shaped nuclei and elongated cytoplasm, 255  
  clusters of spindle cells, 255  
Metastatic lobular carcinoma of breast, with intracytoplasmic lumen, 248  
Metastatic lung adenocarcinoma, 188, 245, 246  
Metastatic mammary ductal carcinoma, 265  
Metastatic melanoma, 15, 128, 253, 267  
  binucleated and plasmacytoid tumor cells, 253  
  prominent nucleoli, 253  
Metastatic merkel cell carcinoma, 16  
Metastatic neoplasms, 37, 235  
Metastatic ovarian papillary serous carcinoma, 267  
Metastatic prostate adenocarcinoma, 266  
Metastatic prostate carcinoma, 129  
  with round to oval nuclei and prominent nucleoli, 249  
  in sheets and clusters, 249  
Metastatic prostatic adenocarcinoma, 249  
Metastatic renal cell carcinoma, 16, 126, 267  
Metastatic sarcomas, 209, 254  
Metastatic signet-ring cell carcinoma, 129, 249  
Metastatic small cell carcinoma, 251, 266  
  clusters of small tumor cells, 251  
  nuclear breakdown, 251  
  nuclear molding and crowding, 251  
Metastatic squamous cell carcinoma, 249, 250, 266  
Metastatic synovial sarcoma, 130  
Metastatic thyroid carcinoma, 267  
Metastatic tumors  
  colorectal adenocarcinoma, 266  
  keratinizing squamous cell carcinoma, 15  
  mammary ductal carcinoma, 265  
  melanoma, 267  
  ovarian papillary serous carcinoma, 267  
  prostate adenocarcinoma, 266  
  renal cell carcinoma, 267  
  small cell carcinoma, 266  
  squamous cell carcinoma, 266  
  thyroid carcinoma, 267  
Metastatic urothelial cell carcinoma, 128, 192, 217, 253  
Meyenburg complex, 176  
Michaelis-Gutmann bodies, 204  
Microphthalmia-associated transcription factor (MiT), 199, 206  
Milan System for Reporting Salivary Gland Cytopathology, 2  
Molecular apocrine, 81  
Motor vehicle accident (MVA), 53, 55  
Mucicarmine, 66, 115, 184, 188, 215, 249  
Mucin special stain, 67  
Mucinous adenocarcinoma, 118, 214  
Mucinous breast carcinoma  
  clinical condition, 75  
  cytology, 75  
  differential diagnosis, 76–77  
  imaging technique, 75  
  molecular profile, 76  
Mucinous cystic neoplasm (MCN), 166, 167  
Mucocele, 76  
Mucoepidermoid carcinoma, 8, 9  
Mucosa-associated lymphoid tissue (MALT), 36, 125, 142, 275  
Multinucleated giant histiocytes, 239  
Multinucleation, 32, 36, 107, 108, 137, 151, 212, 226, 229, 238, 239, 243, 253  
*Mycobacterium*, 60  
Myeloid sarcoma, 284, 285  
Myoepithelial carcinoma (MC), 11, 12  
Myoepithelial cell nuclei, 50, 51  
Myoepithelial cells, 5, 6, 44, 46, 47, 49–52, 74, 76, 90, 97  
Myospherulosis, 55–57  
Myxoid carcinoma, 212
- N**  
National Cancer Institute (NCI), 44  
Necrotizing lymphadenitis, 263  
Negative for intraepithelial lesion or malignancy (NILM), 147  
Neoplastic mucinous cyst, 167–169  
Nephroblastoma, *see* Wilms' tumor  
Neuroendocrine tumors (NETs), 121, 191  
  atypical carcinoids, 122  
  LCNEC, 123  
  SCLC, 122  
  of stomach, 142  
  typical carcinoid tumors, 121

- Neurofibromatosis, 96, 144, 145, 212
- Neutrophils, 4, 111, 112, 241, 263
- Nodular hyperplasia, 21, 22
- Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), 186, 279, 280
- Noncaseating granuloma, 61
- Non-cirrhotic liver, 180, 184, 187
- Non-Hodgkin lymphoma (NHL), 117, 185, 242
- Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), 19–20
- Nonkeratinizing squamous cell carcinoma, 136, 139, 150, 152
- Nonneoplastic salivary gland lesions, 3
- acinar cells
    - high power view, 3
    - low-power view, 3
  - atypical squamous cells, 5
  - granulomatous sialadenitis, 4
  - lymphoepithelial cyst, 4
  - parotid gland cystic lesion
    - diffuse hyperplastic oncocytosis, 3
    - non-tyrosine crystals, 3
  - reactive intraparotid gland lymph nodes, 4
  - resolving acute sialadenitis, 4
- Non-small-cell lung carcinoma (NSCLC), 103
- Noonan syndrome, 59
- Nuclear atypia, 3, 5, 34, 62, 70, 122, 178, 182, 192, 205, 208, 238, 243, 247, 252
- Nuclear hyperchromasia, 62
- Nuclear-cytoplasmic (N:C) ratio, 107
- O**
- Oncocytic carcinoma, 81
- Oncocytoma, 8, 204
- Oral cancer, 135
- Osteoclastic giant cells, 81, 82
- Osteoclast-like giant cells, 61, 63, 65, 66
- Ovary metastatic papillary serous carcinoma, 252, 252, 252, 252, 252
- with papilla, 252
  - with psammoma body, 252
- P**
- Pancreatic ductal adenocarcinoma
- crowded clusters of epithelial cells, 160
  - in EUS-FNA, 169
  - loosely cohesive clusters of, 159, 160
  - loss of honeycomb arrangement, 160
  - mitotic figures, 159, 161
  - nuclear clearing and irregular nuclear contours and grooves, 159, 161
  - prominent mucinous vacuolization, 159, 160
  - single malignant cells with enlarged nuclei and prominent nucleoli, 159, 160
- Pancreatic neuroendocrine neoplasm (PEN), 191
- Pancreatic neuroendocrine tumors (PanNETs)
- bland on ThinPrep, 162
  - chromogranin, stain positive for, 163
  - cytomorphologic features, 161
  - highly cellular aspirate with loose clusters, 161
  - immunohistochemical profiles of, 163
  - nuclear molding and scant cytoplasm, 162
  - predominantly dyscohesive cells with eccentrically placed nuclei, 162
  - pseudorosettes and small clusters, 161
  - salt-and-pepper chromatin and distinct nucleoli, 162
  - synaptophysin, stain positive for, 163
- Pancreaticobiliary tract cytology
- bile duct brushings, 169, 170
  - duodenal epithelium, 157
  - gastric mucosa, 157
  - normal pancreatic elements, 158
  - pancreatic cysts
    - cyst fluid CEA level, 166
    - IPMN, 166
    - MCN, 166
    - mucinous, 166
    - neoplastic mucinous cyst, 167–169
    - non-mucinous, 166
    - pseudocysts, 166
    - serous cystadenoma, 166
- Papanicolaou society of cytopathology system, 157
- solid pancreatic masses, 159
- ACC, 163, 164
  - crowded clusters of epithelial cells, 159, 160
  - loss of honeycomb arrangement, 159, 160
  - pancreatic ductal adenocarcinoma, 159
  - pancreatitis, 159
  - PanNETs, 161, 163
  - SPT, 163, 164
- Papanicolaou method, 175, 192, 204, 236
- Papanicolaou society of cytopathology system, 157
- Papanicolaou stain, 43, 50, 182, 189, 193, 218
- Papanicolaou-stained specimen, 48
- Papillary lesions, 86, 87, 89
- Papillary renal cell carcinoma (PRCC), 89, 201, 206, 209, 210
- Papillary thyroid carcinoma (PTC), 19, 27–32, 196
- follicular variant, 27, 31
  - oncocytic variant, 27, 32
  - tall-cell variant, 27, 31
- Papillary urothelial neoplasms of low malignant potential (PUNLMP), 228
- Papillomas, 86, 87, 228
- Paraneoplastic effusion, 235
- Paris System, 221, 222, 227, 229, 230
- Parotid gland cystic lesion
- diffuse hyperplastic oncocytosis, 3
  - non-tyrosine crystals, 3
- Percutaneous fine needle aspiration biopsy, 173
- Periodic acid-Schiff (PAS) staining, 57
- Pheochromocytoma, 206, 212, 213
- Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), 81
- Phyllodes tumor (PT)
- caveat, 53
  - cytology, 51
  - differential diagnosis, 53
  - fibroepithelial tumor, 51
  - imaging technique, 51
  - molecular profile, 53
- Plasma cell neoplasm, 277
- Pleomorphic adenoma (PA), 5, 6
- Pleomorphic invasive lobular carcinoma, 69
- Pleomorphic lobular carcinoma
- apocrine features, 68
  - cytology, 68
  - differential diagnosis, 69
  - molecular profile, 69
- Pleomorphism, 62, 230
- Pneumocystis carinii* pneumonia (PCP), 106, 112, 114
- Pneumocystis jiroveci* pneumonia, *see Pneumocystis carinii* pneumonia (PCP)



- Polyomaviruses, 223, 225, 226  
 Polysomy, 170  
 Poorly differentiated thyroid carcinoma (PDTC), 34–36  
 Post-chemotherapy, 69  
 Primary bladder squamous cell carcinomas, 230  
 Primary breast lymphoma (PBL), 93  
 Primary effusion lymphoma, 244  
 Primary gastric follicular lymphoma, 143  
 Primary gastric lymphoma, 142  
 Primary hepatic lymphoma (PHL), 185  
 Primary Hodgkin lymphoma of stomach, 143  
 Primary malignant tumors  
   cholangiocarcinoma, 184  
   epithelioid hemangioendothelioma, 187  
   HCC  
     cytological diagnosis, 180  
     endothelial wrapping, 181  
     feature of, 181  
     fibrolamellar variant of, 183  
     Hep Par 1, 181  
     IHC markers, 181  
     incidence of, 180  
     poorly differentiated tumor, 182  
     well-differentiated, 181, 182  
      $\alpha$ -fetoprotein (AFP), 181  
   hepatoblastoma, 183  
   IHC markers, 180  
   lymphoma  
     DLBCL, 185  
     FNAs of, 185  
     HL, 186  
     subtypes, 185  
 Primary mediastinal large B-cell lymphoma (PMBL), 279  
 Primary neuroendocrine tumor, 96  
 Primary nodal hemangioma, 286  
 Primary salivary gland carcinomas  
   acinic cell carcinoma, 11  
   adenocarcinoma, 13  
   adenoid cystic carcinoma, 10, 11  
   carcinoma ex pleomorphic adenoma, 9  
   high-grade carcinoma ex pleomorphic adenoma, 10  
   low-grade myoepithelial carcinoma, 11  
   lymphoepithelial carcinoma, 13  
   mucoepidermoid carcinoma, 8, 9  
   myoepithelial carcinoma, 12  
   secretory carcinoma, 12, 13  
 Primary sclerosing cholangitis (PSC), 169  
 Primitive neuroectodermal tumor (PNET), 194, 196  
 Proliferative breast disease (PBD), 43, 46  
 Prostatic adenocarcinoma, 192, 216, 230, 233, 240  
 Protein tyrosine phosphatase, nonreceptor type 11 gene (*PTPN11*), 59  
 Psammoma bodies, 204, 237, 241  
 Pseudocysts, 166  
 Pseudomyxoma peritonei, 242  
 Pulmonary alveolar proteinosis, 105, 112  
 Pulmonary cytology, 103  
   benign lesions, features of, 106–107  
   lung, metastatic tumors to, 126  
     metastatic breast carcinoma, 126  
     metastatic colonic adenocarcinoma, 127  
     metastatic melanoma, 128  
     metastatic prostate carcinomas, 129  
     metastatic renal cell carcinoma, 126  
     metastatic urothelial cell carcinoma, 128  
     stomach, metastatic signet ring cell carcinoma, 129  
     synovial sarcoma, 130  
     uterus, metastatic carcinoma, 127  
   lung transplantation, 111  
   malignant primary lung tumors, 116  
     ADC, 117–119  
     NETs, 121–123  
     SqCC, 119, 120  
     uncommon pulmonary tumors, 123–125  
   malignant tumors, features of, 117  
   pulmonary alveolar proteinosis, 112  
   pulmonary hamartoma, 113  
   pulmonary infection  
     aspergillosis, 114  
     *candida* infections, 115  
     coccidioidomycosis, 113  
     cryptococcosis, 115  
     PJP, 114  
     strongyloidiasis, 116  
   radiation-induced reactive bronchial epithelial cell changes, 107  
   reactive bronchial epithelial changes, 107  
     benign mesothelial cells, 111  
     bronchial epithelium hyperplasia, 108  
     bronchial reserve cells, 109  
     bronchoalveolar macrophages, 110  
     fragments of cartilage, 110  
     goblet cell hyperplasia, 108  
     reactive squamous cells, 109  
   sarcoidosis and granulomatous inflammation, 112  
   specimens of, 104  
     BAL and washing, 105  
     EBUS-TBNA, 105  
     endoscopic transesophageal FNA, 106  
     EUS-FNA, 105  
     invasive procedures, 106  
     sputum, 104  
     TBNA, 104, 105  
     transthoracic FNA, 105  
 Pulmonary hamartoma, 104, 110, 113  
 Pulmonary infection  
   aspergillosis, 114  
   *candida* infections, 115  
   coccidioidomycosis, 113  
   cryptococcosis, 115  
   PJP, 114  
   strongyloidiasis, 116
- R**  
 Rapid on-site evaluation (ROSE), 1–2  
 Reactive bronchial atypia, 107  
 Reactive bronchial cells, 106, 118  
 Reactive bronchial epithelial cells, 107, 108, 118  
 Reactive lymphoid hyperplasia  
   dermatopathic lymphadenitis, 261, 263  
   follicular hyperplasia  
     flow cytometry, 260–262  
     FNA, 260  
     histology, 260, 261  
     molecular study, 261, 262  
   lymphoma molecular study, 261, 262  
 Reactive mesothelial cells, 237–239  
   binucleation, 238  
   prominent nucleoli, 238  
   signet-ring cell morphology, 239  
   variation of nuclei and prominent nucleoli, 238  
 Reactive squamous cells, 109  
 Reed-Sternberg cells, 177, 186

- Renal cell carcinoma (RCC), 190, 197, 199, 208  
 Renal oncocytoma, 204, 205  
 Resolving acute sialadenitis, 4  
 Rhabdomyosarcoma, 14, 194, 254  
 Ribonucleotide reductase catalytic subunit M1 (RRM1), 81  
 Rosette-like pattern, 66
- S**
- Salivary gland  
 fine needle aspiration, 3–15  
 application, 1  
 benign epithelial neoplasms (*see* Benign epithelial neoplasms)  
 hematology lymphoid tumors, 15  
 immunohistochemical markers, 2  
 masses or cystic lesions, 1  
 mesenchymal tumors (*see* Mesenchymal tumors)  
 Milan System for Reporting Salivary Gland Cytopathology, 2  
 molecular biomarkers, 2  
 morphologic features, 1  
 nonneoplastic lesions (*see* Nonneoplastic salivary gland lesions)  
 primary salivary gland carcinomas (*see* Primary salivary gland carcinomas)  
 secondary malignant tumors, 15–16  
 The Milan System for Reporting Salivary Gland Cytopathology, 2  
 World Health Organization histologic classifications, 1
- San Joaquin Valley fever, 113  
 Sarcoidosis, 112  
 Sarcomas, 117, 242  
 Sarcomatoid renal cell carcinoma, 209  
 Sarcomatoid squamous cell carcinoma, 120  
 Sarcomatous transformation, 52  
*Schistosoma haematobium*, 226  
 Schistosomiasis, 226  
 Scirrhous breast carcinoma, 59  
 Sclerosing adenosis, 74  
 Secondary malignant tumors, 15–16  
 Secretory carcinoma, 12, 13, 81  
 Serous cavities, 235, 242, 244, 254  
 Serous cystadenoma, 166, 167  
 Serous effusion  
 benign and reactive changes, 236  
 acute inflammatory effusion, 241  
 benign histiocytes, 239  
 benign mesothelial cells, 236  
 EPE, 240  
 lymphocytic effusion, 239, 240  
 psammoma bodies, 241  
 reactive mesothelial cells, 238, 239  
 benign, findings in, 237  
 malignant, findings in, 242  
 malignant pleural effusion, 241, 242  
 bladder urothelial cell carcinoma, 252, 253  
 colorectal adenocarcinomas, 247  
 malignant mesothelioma, 243  
 metastatic adenocarcinomas, 245  
 metastatic breast carcinoma, 247, 248  
 metastatic diffuse large B-cell lymphoma, 254  
 metastatic epithelioid angiosarcoma, 255  
 metastatic leiomyosarcoma, 255  
 metastatic lung adenocarcinoma, 245, 246  
 metastatic melanoma, 253  
 metastatic prostatic adenocarcinoma, 249  
 metastatic sarcomas, 254  
 metastatic signet-ring cell carcinoma, 249  
 metastatic small cell carcinoma, 251  
 metastatic squamous cell carcinoma, 249, 250  
 ovary, metastatic papillary serous carcinoma of, 252  
 PEL, 244  
 serous fluid  
 collection and specimen preparation, 236  
 types of, 236
- Sinus histiocytosis, 261  
 Small B-cell lymphocytic lymphoma (SLL), 185, 186  
 Small-cell carcinoma, 95, 117, 191, 217, 242  
 Small-cell lung carcinoma (SCLC), 103, 109, 122  
 Solid pseudopapillary tumor (SPT), 163  
 cell block sections, 165  
 cytomorphologic features, 163  
 hyaline globules, 165  
 negative E-cadherin immunostain, 165  
 nuclear staining for beta-catenin, 165  
 vascular stalks lined by neoplastic cells, 164
- SOX10, 128, 193, 218, 253  
 Sputum, 104, 105, 115, 116, 119  
 Squamous cell abnormalities  
 atypical squamous cells, 150  
 HSIL, 150  
 LSIL, 150  
 squamous cell carcinoma, 150
- Squamous cell carcinoma (SqCC), 103, 104, 106, 117, 119, 120, 189, 213, 242  
 of esophagus, 139, 140, 215  
 with sarcomatoid feature, 120
- Stroma fragment, 49, 50  
*Strongyloides stercoralis*, 116  
 Strongyloidiasis, 116  
 Subacute thyroiditis, 24  
 Subareolar breast abscess  
 caveat, 59  
 clinical condition, 58  
 cytology, 58  
 differential diagnosis, 59
- Superficial lesion, 133  
 Superficial umbrella cells, 222  
 Suspicious for follicular neoplasm (SFN), 19, 39  
 Suspicious for malignancy (SFM), 42  
 suspicious urothelial cells, 227, 228  
 Syringomatous adenoma, 74
- T**
- T-cell acute lymphoblastic leukemia/lymphoma (T-ALL), 284  
 Terminal duct lobular unit (TDLU), 46  
 Tetrasomy, 170, 199  
 The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), 19  
 The Cancer Genome Atlas (TCGA), 199  
 The Milan System for Reporting Salivary Gland Cytopathology, 2  
 Thymidylate synthase (TS), 81  
 Thyroid and Cervical Cytology, 221  
 Thyroid aspirates, 19  
 Thyroid nodules  
 AUS/FLUS, 37–39  
 benign and malignant thyroid lesions, 20  
 benign entities  
 amyloid nodule, 26  
 black thyroid, 26  
 colloid nodules, 21

- infectious thyroiditis, 25
  - lymphocytic (Hashimoto's) thyroiditis, 23
  - nodular hyperplasia, 21, 22
  - subacute thyroiditis, 24
  - cytologic diagnosis, 20
  - diagnostics, 19
  - FN/SFN, 39–42
  - malignant entities
    - ATC, 36
    - lymphomas, 36
    - metastatic neoplasms, 37
    - MTC, 32–34
    - PDTC, 34–36
    - PTC, 27–32
  - nondiagnostic/unsatisfactory specimens, 20–21
  - palpation-guided and ultrasound-guided FNAs, 19
  - SFM, 42
  - TBSRTC, 19
  - thyroid aspirates, 19
  - Tight epithelial cluster, 49, 50
  - Tight junctions, 84
  - Transgelin (*TAGLN*), 79
  - Transthoracic fine needle aspiration, 105
  - Tridimensional breast lobe fragment, 46
  - Tridimensional clusters, 50, 134
  - Triple-negative breast cancers, 79, 92
  - Trisomy, 170, 199
  - Tubular adenoma, 53
  - Tubular breast carcinoma, 71
    - clinical condition, 70
    - cytology, 70
    - differential diagnosis, 74
    - imaging technique, 70
    - molecular profile, 74
  - Tumor necrosis factor (TNF) receptor, 79
  - Tumor-infiltrating lymphocytes (TILs), 79
  - Type II pneumocytes hyperplasia, 106
  - Typical carcinoid, 121
  - Tyrosine kinase inhibitors (TKI), 236, 245
- U**
- Undifferentiated carcinoma, 127, 242
  - Undifferentiated large-cell carcinoma, 117
  - Urine carcinomas
    - reactive conditions
      - HSV, 226
      - lithiasis, 226
      - polyomaviruses, 223, 226
      - reactive urothelial cells, 223, 224
    - schistosomiasis, 226
    - treatment-related changes, 226
  - specimen collection methods
    - from neobladder, 223
    - instrumented urines, 222, 223
    - voided urine specimens, 222
  - urothelial atypia
    - atypical urothelial cells, 227
    - suspicious urothelial cells, 227, 228
  - urothelial neoplasms
    - high-grade urothelial neoplasms, 229, 230
    - low-grade urothelial neoplasms, 228, 229
    - metastasis, 230
- Urine cytology
- normal cellular elements, 222
  - normal elements, 223
  - urine carcinomas (*see* Urine carcinomas)
  - urothelial carcinoma
    - Paris System for Reporting Urinary Cytology*, 221
    - risk factors, 221
    - sensitivity for low-grade, 221
    - specimens, 221
- Urothelial cell carcinoma, 192, 211, 217, 218
- Uterus, metastatic carcinoma, 127
- V**
- Vancouver classification, 206
  - Vascular tumors, 124, 286
  - VHL pathway, 199
  - Video-assisted mediastinoscopy (VAM), 106
  - Video-assisted thoracoscopy (VATS), 106
  - Von Hippel-Lindau syndrome, 212
  - von Meyenburg complex, 176
- W**
- Warthin tumor, 6, 7
  - Weiss score, 211
  - Wilms' tumor, 183, 194, 207
- X**
- X-linked form, 136
  - Xp11 translocation-associated renal cell carcinoma (Xp11 TRCC), 207, 210
- Z**
- Zollinger-Ellison syndrome, 142